MX2020000713A - Metodos de aferesis y sus usos. - Google Patents
Metodos de aferesis y sus usos.Info
- Publication number
- MX2020000713A MX2020000713A MX2020000713A MX2020000713A MX2020000713A MX 2020000713 A MX2020000713 A MX 2020000713A MX 2020000713 A MX2020000713 A MX 2020000713A MX 2020000713 A MX2020000713 A MX 2020000713A MX 2020000713 A MX2020000713 A MX 2020000713A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- apheresis methods
- protein
- treating
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1678—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes intracorporal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Anesthesiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
Abstract
Se proporcionan métodos de tratamiento, de un sujeto en necesidad de tratamiento, para una enfermedad ocasionada por una pérdida de función o actividad de una proteína. También se proporcionan métodos de tratamiento, de un sujeto en necesidad de tratamiento, para una enfermedad ocasionada por una ganancia de función, actividad o expresión de una proteína.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762533579P | 2017-07-17 | 2017-07-17 | |
PCT/US2018/042553 WO2019018439A1 (en) | 2017-07-17 | 2018-07-17 | APHERESE METHODS AND ASSOCIATED USES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020000713A true MX2020000713A (es) | 2020-08-31 |
Family
ID=65016674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020000713A MX2020000713A (es) | 2017-07-17 | 2018-07-17 | Metodos de aferesis y sus usos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200164008A1 (es) |
EP (1) | EP3655001A4 (es) |
JP (2) | JP2020530834A (es) |
CN (1) | CN111225677A (es) |
AU (1) | AU2018304194A1 (es) |
BR (1) | BR112020000995A2 (es) |
CA (1) | CA3069880A1 (es) |
MX (1) | MX2020000713A (es) |
WO (1) | WO2019018439A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3006569A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
IL295070A (en) | 2020-01-28 | 2022-09-01 | Freeline Therapeutics Ltd | An improved test for determining the value of neutralizing antibodies to a viral vector |
CN111500635B (zh) * | 2020-07-02 | 2020-10-09 | 北京大学第三医院(北京大学第三临床医学院) | 一种包含携带核酸分子的载体的试剂盒 |
RU2020122141A (ru) * | 2020-07-03 | 2022-01-04 | Максим Петрович Никитин | Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови |
CA3192748A1 (en) | 2020-09-23 | 2022-03-31 | Oskar SMRZKA | Compound for increasing efficacy of viral vectors |
WO2023064382A1 (en) * | 2021-10-16 | 2023-04-20 | Isaac Eliaz | Apheresis of whole blood |
WO2023180502A1 (en) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0804734B1 (en) * | 1994-05-13 | 2005-05-04 | Miltenyi Biotec GmbH | Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood |
US6406861B1 (en) * | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
JP4662665B2 (ja) * | 1999-06-03 | 2011-03-30 | アドバンスト エクストラバスキュラー システムズ | 循環血液からの好ましくない分子の一段階除去 |
US6464976B1 (en) * | 1999-09-07 | 2002-10-15 | Canji, Inc. | Methods and compositions for reducing immune response |
US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
JP2010131033A (ja) * | 2007-03-16 | 2010-06-17 | Medical Science Co Ltd | 医療用吸着剤 |
US8123713B2 (en) * | 2008-08-12 | 2012-02-28 | Caridian Bct, Inc. | System and method for collecting plasma protein fractions from separated blood components |
WO2011117258A2 (en) * | 2010-03-22 | 2011-09-29 | Association Institut De Myologie | Methods of increasing efficiency of vector penetration of target tissue |
US20130068691A1 (en) * | 2011-08-05 | 2013-03-21 | Henry John Smith | Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders |
ES2857773T5 (es) * | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
US9434928B2 (en) * | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
AU2013221212B2 (en) * | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
US9717841B2 (en) * | 2012-09-11 | 2017-08-01 | Gary L. McNeil | Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source |
ES2774966T3 (es) * | 2013-07-22 | 2020-07-23 | Childrens Hospital Philadelphia | Variantes de aav y composiciones, métodos y usos para la transferencia de genes a células, órganos y tejidos |
JP2017531652A (ja) * | 2014-10-06 | 2017-10-26 | アルスロジェン ビー.ブイ.Arthrogen B.V. | Aavに基づく遺伝子治療 |
EP3054007A1 (en) * | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
US20180093032A1 (en) * | 2016-08-15 | 2018-04-05 | Henry John Smith | Targeted apheresis using binding agents or ligands immobilized on membranes |
CA3045551A1 (en) * | 2016-12-16 | 2018-06-21 | Uniqure Ip B.V. | Immunoadsorption |
EP3589311A1 (en) * | 2017-03-02 | 2020-01-08 | Genethon | Method for removing anti-aav antibodies from a blood-derived composition |
US20210317474A1 (en) * | 2017-11-08 | 2021-10-14 | Novartis Ag | Means and method for producing and purifying viral vectors |
-
2018
- 2018-07-17 AU AU2018304194A patent/AU2018304194A1/en active Pending
- 2018-07-17 CA CA3069880A patent/CA3069880A1/en active Pending
- 2018-07-17 JP JP2020502112A patent/JP2020530834A/ja active Pending
- 2018-07-17 WO PCT/US2018/042553 patent/WO2019018439A1/en unknown
- 2018-07-17 CN CN201880060309.6A patent/CN111225677A/zh active Pending
- 2018-07-17 EP EP18835932.7A patent/EP3655001A4/en active Pending
- 2018-07-17 US US16/631,692 patent/US20200164008A1/en active Pending
- 2018-07-17 MX MX2020000713A patent/MX2020000713A/es unknown
- 2018-07-17 BR BR112020000995-4A patent/BR112020000995A2/pt unknown
-
2023
- 2023-08-23 JP JP2023135227A patent/JP2023179414A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3655001A1 (en) | 2020-05-27 |
BR112020000995A2 (pt) | 2020-09-08 |
CN111225677A (zh) | 2020-06-02 |
CA3069880A1 (en) | 2019-01-24 |
WO2019018439A1 (en) | 2019-01-24 |
EP3655001A4 (en) | 2021-04-28 |
JP2023179414A (ja) | 2023-12-19 |
US20200164008A1 (en) | 2020-05-28 |
JP2020530834A (ja) | 2020-10-29 |
AU2018304194A1 (en) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020000713A (es) | Metodos de aferesis y sus usos. | |
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
MX2020001340A (es) | Modelos celulares y terapias para enfermedades oculares. | |
EP4219724A3 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2018015853A (es) | Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137). | |
PH12020552229A1 (en) | Il-11ra antibodies | |
MX2019007256A (es) | Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano. | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
MX2017003797A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
EA201991997A1 (ru) | Комбинированная терапия | |
AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
AU2018337076A1 (en) | Method of treatment | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
EA201991360A1 (ru) | Модифицированные олигонуклеотиды для лечения поликистозной болезни почек | |
JOP20190164B1 (ar) | تركيبات وطرق لعلاج داء فاربر | |
EP3850547A4 (en) | SYSTEM AND PROCESS FOR MANUFACTURE AND TREATMENT OF FUR, SKIN AND LEATHER GOODS | |
MX2017013819A (es) | Metodos para la reduccion de grasa. |